| Literature DB >> 30136122 |
Zhenyou Zou1,2, Qiqiong Shen3, Yanxia Pang4, Xin Li3, Yongfeng Chen3, Xinjuan Wang3, Xinhua Luo5, Zhongmin Wu3, Zhaosheng Bao3, Juanli Zhang3, Jiawei Liang3, Lingjia Kong3, Lunan Yan3, Lijun Xiong3, Tianjun Zhu3, Shuaibin Yuan3, Miaoyang Wang3, Kewei Cai3, Yinning Yao3, Jianchao Wu3, Yuding Jiang3, Heng Liu3, Jing Liu3, Yan Zhou3, Qianqian Dong3, Wei Wang3, Kangjie Zhu3, Li Li6, Yingjie Lou3, Hongdian Wang3, Yizi Li3, Hong Lin3.
Abstract
Alzheimer's disease (AD) is currently incurable and places a large burden on the caregivers of AD patients. In the AD brain, iron is abundant, catalyzing free radicals and impairing neurons. The blood-brain barrier hampers antidementia drug delivery via circulation to the brain, which limits the therapeutic effects of drugs. Here, according to the method described by Gobinda, we synthesized a 16 lysine (K) residue-linked low-density lipoprotein receptor-related protein (LRP)-binding amino acid segment of apolipoprotein E (K16APoE). By mixing this protein with our designed therapeutic peptide HAYED, we successfully transported HAYED into an AD model mouse brain, and the peptide scavenged excess iron and radicals and decreased the necrosis of neurons, thus easing AD.Entities:
Keywords: Alzheimer’s disease; Blood-brain barrier; HAYED peptide; Iron; K16APoE; Radical
Mesh：
Substances：
Year: 2019 PMID： 30136122 DOI： 10.1007/s13346-018-0579-4
Source DB: PubMed Journal: Drug Deliv Transl Res ISSN： 2190-393X Impact factor: 4.617